

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

**SULIQUA** ▼  
insulin glargine (100 units/mL) & lixisenatide

## GUIDE FOR PATIENTS AND/OR CAREGIVERS

This card is provided only as a guide to avoid medication errors. Before using Suliqua®, you must be trained on how to use the Suliqua SoloStar® pen by your healthcare professional, and you must carefully read the patient leaflet and the instructions for use accompanying the pen.

Keep this card. You may need to refer to it again. Write your name on this card: \_\_\_\_\_


### IMPORTANT INFORMATION ON THE PENS

SULIQUA is available in 2 pre-filled pens containing 2 different strengths of lixisenatide, and different dose ranges of insulin glargine 100 units/mL. Your healthcare professional has prescribed one of the pens described below that is right for your insulin needs.

SULIQUA pre-filled pens simultaneously deliver insulin glargine and lixisenatide in a single, once-daily injection.

#### SULIQUA 10-40 PEN

SULIQUA 100 UNITS/mL + 50 MICROGRAMS/mL SOLUTION FOR INJECTION IN A PRE-FILLED PEN



- Insulin glargine (100 units/mL): 10 – 40 Units/day
- Lixisenatide (50 mcg/mL): 5 – 20 mcg/day
- This pen allows a single once-daily injection of a dose between 10 and 40 dose steps
- This pen is peach coloured with an orange injection button

#### SULIQUA 30-60 PEN

SULIQUA 100 UNITS/mL + 33 MICROGRAMS/mL SOLUTION FOR INJECTION IN A PRE-FILLED PEN



- Insulin glargine (100 units/mL): 30 – 60 Units/day
- Lixisenatide (33 mcg/mL): 10 – 20 mcg/day
- This pen allows a single once-daily injection of a dose between 30 and 60 dose steps
- This pen is olive coloured with a brown injection button

• **The prescription should mention which SULIQUA pre-filled pen type you need: the peach coloured pen or the olive coloured pen and the number of dose steps to be injected.**

- Check with your pharmacist if the pen is a different colour than the one you are used to.
- One dose step contains one unit of insulin glargine 100 units/mL plus a corresponding amount of lixisenatide. **Before you use SULIQUA, be clear on how many dose steps you require.** Your healthcare professional will have provided you with this information.
- The dose pointer of the pre-filled pen device shows the number of dose steps to be injected.

## GUIDE FOR PATIENTS AND/OR CAREGIVERS

### TAKE NOTE:

- **SULIQUA is supplied in a pre-filled pen and must only be used with this device otherwise dosing errors and serious harm can result. Patients, caregivers, and healthcare professionals must never use a syringe to withdraw SULIQUA from a pre-filled pen.** Ask your Healthcare professional if you need further guidance on how to use the pen correctly.
- **A new needle must always be attached before each use. Needles must not be re-used.**
- For SULIQUA, one dose step always contains one unit of insulin glargine 100 units/mL, regardless of the SULIQUA pre-filled pen being used.
- Your healthcare professional can explain the design and features of your SULIQUA SoloStar pen, including how the dose counter of the pre-filled pen device shows the number of dose steps to be injected.
- During the switch to this type of combination medicine and in the weeks after the switch, you should measure your blood sugar levels more frequently. Your doctor will provide recommendations on how to make dose adjustment based on your fasting plasma glucose.
- If you have any questions about your treatment, speak to your healthcare professional.

### BEFORE INJECTING SULIQUA



Carefully read the instructions for use and the patient information leaflet that come with the package leaflet.



If you do not follow all of these instructions, you may get too much or too little medication.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. See paragraph below for how to report side effects.

#### Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information Leaflet.

You can also report side effects directly via the Yellow Card Scheme at: [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

Side effects should also be reported to the Sanofi drug safety department on 0800 0902314.  
Email: [uk-drugsafety@sanofi.com](mailto:uk-drugsafety@sanofi.com)